At Stem Cells Transplant Institute in Costa Rica, we offer stem cell therapy for peripheral neuropathy to support nerve comfort, improve circulation, and reduce inflammation, including diabetic neuropathy.
Peripheral neuropathy occurs when nerves in the legs, feet, or hands become damaged—often due to high blood sugar, poor circulation, or chronic inflammation. Causes of neuropathy can include genetics, infections and inflammatory conditions, toxic exposures, alcoholism, medications, or kidney failure, and in some individuals the exact contributing cause may be difficult to identify.
According to the International Diabetes Federation (2023), estimates suggest that up to 50% of people with diabetes may develop some form of neuropathy during their lifetime.
Stem cell therapy is being studied as a research-based approach that may help support nerve health by modulating inflammatory processes and supporting a tissue environment associated with healthier nerve communication (including myelin-related repair mechanisms in preclinical research).
At Stem Cells Transplant Institute, MSC therapy can be used to help treat peripheral neuropathies — including diabetic neuropathies. Treatment is delivered in San José, Costa Rica within a certified clinical facility under direct physician supervision.
These programs are designed for patients exploring investigational options beyond symptomatic management. While medications such as gabapentin or duloxetine may help reduce neuropathic pain, they do not directly address underlying nerve or microvascular damage. Regenerative protocols utilizing mesenchymal stem cells (MSCs) aim to support the biological environment surrounding affected nerves.
Patients from the United States, Canada, and Europe travel to San José to access regenerative medicine programs delivered within a structured clinical environment.
Before scheduling therapy, all patients undergo a comprehensive medical evaluation to assess candidacy. This review is tailored to the underlying cause of neuropathy and may include:For diabetic patients, HbA1c, kidney function, and glycemic control; for post-chemotherapy neuropathy, oncological history and current treatment status are assessed.
Research suggests that MSCs may help support neuropathy by modulating processes associated with new blood vessel formation and by supporting myelin-related repair mechanisms observed in preclinical and early clinical research, which may help improve nerve signaling.
MSCs are also studied for their ability to release trophic factors that may help reduce nerve inflammation, mitigate oxidative stress in nerve tissues, promote a more balanced immune response, and support overall tissue healing
MSC therapy is complementary and adjunctive, meaning it works best alongside standard diabetes care, glucose management, medication, and lifestyle support.
Evidence remains preliminary, and ongoing clinical trials are required to confirm these effects.
Chronic inflammation contributes to nerve pain and degeneration. MSCs naturally release immunomodulatory and anti-inflammatory molecules that may help calm irritated nerves (Zhang et al., 2020).
Diabetic neuropathy is often associated with reduced blood flow to nerves. MSCs may help support small-vessel function and oxygen delivery to nerve tissue through pro-angiogenic and trophic signaling (Shibata et al., 2019).
MSC-derived factors may help reduce oxidative stress— a major contributor to nerve damage in diabetes (Kim et al., 2018).
Some MSC studies report improvements in nerve conduction and structural nerve recovery, suggesting that stem cells may help support natural repair processes (Nagpal et al., 2021).
Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:
*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy for Peripheral Neuropathy (Diabetic neuropathy) remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.
Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for Peripheral Neuropathy (Diabetic neuropathy) may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.
*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in Peripheral Neuropathy (Diabetic neuropathy) remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.
No. Stem cells cannot cure neuropathy. However, research suggests they may help support nerve health by modulating inflammatory processes and supporting overall comfort in some patients when used as an adjunct to standard medical care. Results vary between individuals.
Our protocols use mesenchymal stem cells (MSCs) derived either from a patient’s own tissue or from donated umbilical cord tissue, depending on individual medical evaluation and protocol suitability under Costa Rican medical regulations.
Yes. Good glucose control is important because uncontrolled diabetes can continue to damage nerves over time. Any MSC-based procedure should be combined with consistent diabetes care and ongoing medical management.
In published studies, reported changes-when they occur- often develop gradually over approximately 1–6 months. Timelines vary based on factors such as the severity and duration of nerve damage, overall health, and diabetes control, and some patients may not notice meaningful changes.
Stem cell therapy for peripheral neuropathy can help improve nerve function and reduce symptoms like pain, tingling, and numbness. It works by reducing inflammation, improving blood flow, and supporting nerve repair. While it is not a cure, many patients experience better nerve comfort and improved quality of life.
Systematic review and meta-analysis of human studies evaluating safety and clinical efficacy of stem cell therapy for diabetic peripheral neuropathy.
View published study
Scientific review examining therapeutic mechanisms, clinical potential, and regenerative effects of stem cell therapy in diabetic neuropathic pain.
View published study
Research review describing how mesenchymal stem cell–derived exosomes may support nerve repair and functional recovery in neuropathy conditions.
View published study
Scientific review discussing translational challenges, mechanisms, and therapeutic prospects of mesenchymal stem cell therapy for diabetic neuropathy.
View published study
San José, Costa Rica
info@stemcellstransplantinstitute.com
+1 888 785-4170
